Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioMarck Pharmaceuticals, Ltd.

http://www.biomarck.com/

Latest From BioMarck Pharmaceuticals, Ltd.

Pipeline Watch: Top-Line Data For Reslizumab, Erenumab And Biosimilar Rituximab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Commentary: Private investment round-up for April 2009

Investments in private pharmaceutical and biotech companies slumped by 24% in April, with the market being once again dominated by US companies, a Scrip analysis has found.

Respiratory Germany

A Brighter Outlook for New Cystic Fibrosis Drugs

The pipeline of new medicines to combat cystic fibrosis has risen dramatically thanks to funding support from philanthropic organizations such as the Cystic Fibrosis Foundation and venture capitalists. As more compounds demonstrate proof-of-concept, look for Big Pharma to move into the area too, lured by the possibility of label expansion beyond CF into more widespread diseases such as asthma and COPD.

BioPharmaceutical Business Strategies

BioMarck Pharmaceuticals Ltd.

BioMarck Pharmaceuticals is studying the role of the MARCKS protein (myristoylated alanine-rich C kinase substrate) in chronic obstructive pulmonary disease and diseases like asthma and cystic fibrosis. In each of these diseases, excessive amounts of mucus are secreted, which leads to obstruction of the lung airways. Experiments in mice showed that inhibiting the protein led to decreased mucus secretion, reduced inflammation in the lungs, and improvements in lung air flow.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register